2023 International Conference on Intelligent Technologies for Sustainable Electric and Communications Systems (iTech SECOM) | 979-8-3503-7118-5/23/$31.00 ©2023 IEEE | DOI: 10.1109/iTechSECOM59882.2023.10435323

Ethical Dimensions and Future Prospects of Artificial Intelligence in Decision Making Systems for Oncology: A Comprehensive Analysis and Reference Scheme

Arivoli Sundaramurthy
Department of Biomedical Engineering
K S R Institute for Engineering and Technology
Tamilnadu, India
arivolis_bme@ksriet.ac.in

Chitra Vaithiyalingam
Department of Mathematics
PSG Institute of Technology and Applied Research
Tamilnadu, India
chitra@psgitech.ac.in

***Abstract*—Artificial Intelligence (AI) has become a prevalent force in diverse medical domains, including image diagnostics, pathological categorization, treatment plan selection, and prognosis analysis. The collaboration between human and computer interactions has notably matured in the context of image-assisted cancer diagnosis. However, the ethical considerations associated with the incorporation of AI into clinical decision-making processes remain inadequately addressed. Consequently, the AI-driven Clinical Decision making System has not fully embraced interactions between humans and computers, particularly in the domain of image-supported diagnostic systems. This paper comprehensively reviews the global applications of the Clinical Decision Support System (CDSS) and delineates the fundamental principles guiding the incorporation of AI into CDSS. It scrutinizes the challenges faced by AI in oncology decision-making, shedding light on the existing ethical gaps. By presenting a thorough overview of the current landscape, this paper serves as a attribute framework for the future deployment of Artificial Intelligence in the field of oncology decision-making. As AI continues to progress, acknowledging and resolving ethical considerations becomes crucial for unlocking its full potential in enhancing clinical decision-making processes.**

***Keywords*—clinical decision-making process, Artificial intelligence, clinical decision support system , cancer diagnosis**

I. INTRODUCTION

In the time of accurate medication, the quick extension of new medications and endorsed signs presents huge difficulties in concocting ideal treatment plans for particular sub-atomic aggregates across different growths [1]-[3]. The coming of clinical choice emotionally supportive networks (CDSS) in light of man-made consciousness (computer based intelligence) [4]-[6], worked with by huge information and AI, has arisen as an answer for these intricacies. This computer based intelligence driven CDSS incorporates different clinical records, writing, and clinical exploration information to survey factors like medication adequacy, item openness, unfriendly responses, patient monetary status, and clinical protection types. Thus, it gives fitted ideas to help clinicians in advancing treatment plans [7],[8]. The utilization of simulated intelligence have reached out past regular critical thinking to incorporate different clinical expert spaces, including picture and obsessive finding, clinical treatment independent direction, anticipation examination, and new medication screening [9], [10]. IBM's Watson framework, applied across different areas like style, finance, clinical therapy, the travel industry, regulation, schooling, and transportation, has prominently succeeded in disease care through Watson for Oncology (WFO). WFO, a generally embraced CDSS, has acquired worldwide notoriety in tending to cellular breakdown in the lungs, colon malignant growth, rectal disease, bosom disease, gastric malignant growth, and gynaecological disease. Leveraging structured case data input, WFO rapidly outputs standardized treatment recommendations within a minute, offering highly consistent evidence and serving over 70 municipal medical institutions and tens of thousands of patients.

Advancements in artificial intelligence have increasingly permeated the field of medical services, notably in oncology, significantly contributing to enhancing the precision, efficiency, and personalized nature of disease treatment systems. However, the ethical considerations involved in implementing AI in clinical decision support demand meticulous scrutiny within healthcare guidance. This paper meticulously explores and comprehensively analyzes the ethical dilemmas associated with integrating AI into oncology-focused Clinical Decision Support Systems (CDSS), delving into concerns encompassing patient privacy, informed consent, bias reduction, and the impact of automated decision-making in the delicate realm of cancer care. Moreover, the paper endeavors to establish a framework—a reference scheme—that accounts for these ethical dimensions, aiming to guide the conscientious development and deployment of AI-powered CDSS in oncology. By navigating the intricate intersection between technology and healthcare ethics, this paper significantly contributes to the ongoing discussion concerning the responsible and beneficial assimilation of AI into clinical decision support systems for oncology, providing invaluable insights essential for researchers and practitioners alike in this field.

Another vital CDSS, the Chinese Society of Clinical Oncology-Man-made consciousness (CSCO artificial intelligence) framework, in light of the Chinese Society of Clinical Oncology-Bosom Malignant growth (CSCO BC) around 15%. Moreover, contrasts in drug accessibility, patients' inclinations, monetary contemplation, and protection inclusion add to irregularities. In 7% of cases, differences among WFO and MDT proposals were ascribed to varieties in administrative endorsement processes between nations, recommending the need to integrate privately supported treatments into the CDSS information base. Different irregularities emerged because of contrasts in treatment strategies impacted by segment attributes and patient subgroup contemplation.

Clinical exploration of CDSS faces a few difficulties. Existing examinations frequently have small example sizes, and many need to address unsupported cases, influencing the general productivity of clinical use. Regardless of the commonality of specialists contributing cases into CDSS with the framework and critical components during the diagram survey, the quality and repeatability of these undertakings still need to be improved, possibly affecting CDSS suggestions. While CDSS gives proof to navigation, oncologists might examine this proof and re-evaluate proposals considering Multi-Disciplinary Group assessments. Even though CDSS utilization advances normalized treatment, individual inclinations and mental predispositions could prompt non-unbiasedly normalized treatment choices. Notably, the absence of consistency doesn't suggest that proposals from MDT or CDSS are intrinsically mistaken, as contrasts might be made sense of by different elements, remembering varieties of treatment strategies for co morbid or maturing patients.

V. ADVANCING DEVELOPMENT IN CLINICAL DECISION SUPPORT SYSTEMS (CDSS)

The trajectory for advancing CDSS is marked by several key directions. Firstly, there is a crucial need to further elevate the update rate of the knowledge base. Secondly, incorporating abundant input information and structured knowledge base data during training is instrumental in reducing unsupported cases. Thirdly, fostering an open CDSS feedback port, involving Multi-Disciplinary Team (MDT) discussions when there is no support for specific cases, contributes to continuous learning. The feedback loop also extends to dynamic changes in treatment plans suggested by the CDSS. Fourth, a pivotal step involves quantifying and evaluating the recommendation level of CDSS for treatment decision-making based on the wealth of evidence. Lastly, as CDSS is introduced globally, localization of diagnosis and treatment equipment and drugs becomes imperative to enhance accessibility.

While the storage capacity of an AI-based CDSS surpasses that of the human brain, significant improvements are needed to adapt to real-world medical environments. This encompasses standardizing and sharing nationwide medical data, refining follow-up systems, and establishing unique medical data warehouses tailored to different countries. Integrating this data with international guidelines and medical systems ensures that CDSS realizes its full potential in serving diverse patient populations globally.

It is urgent to highlight that, right now, CDSS can't supplant the job of oncologists; instead, it should be viewed as an essential partner or coach for youthful specialists. The idea of cooperative insight, where human and artificial intelligence synergize, arises unmistakably. While CDSS rapidly develops, reliance should not be blind, as medicine encompasses various factors, including social and psychological aspects. The future envisions a collaborative intelligence model where CDSS supports clinicians, offering consistent therapeutic options while acknowledging the intricate nature of medical decision-making. Specialists, particularly oncologists, stay essential in fitting individualized measures for patients, considering factors like physical and mental status, monetary contemplation, entanglements, and readiness to get treatment after CDSS gives beginning ideas

VI. CONCLUSION

The integration between Clinical Decision Support Systems and Multi-Disciplinary Teams signifies the advancement of artificial intelligence technology. However, this convergence is influenced by external factors like drug availability, adherence to professional guidelines, and the expertise gained through training. The significant value proposition of AI-based CDSS becomes apparent in its ability to provide valuable treatment recommendations for tumors, especially in healthcare settings lacking access to specialized resources. As CDSS transitions into a supportive role, continuous scientific exploration and innovation remain critical. The ever-evolving landscape of medicine highlights the necessity to adapt to emerging challenges, while the collaborative incorporation of AI with medical professionals underscores a comprehensive approach to patient care. This evolution also prompts ethical considerations, highlighting the importance of responsible and transparent implementation of AI in healthcare. Ultimately, ongoing exploration of CDSS holds the potential to drive medical advancements and improve patient outcomes.

REFERENCES

[1] K. Park, “A review of computational drug repurposing,” Translational and Clinical Pharmacology, vol. 27, no. 2, p. 59, 2019.

[2] M. F. Berger and E. R. Mardis, “The Emerging Clinical Relevance of Genomics in Cancer Medicine,” Nature Reviews Clinical Oncology, vol. 15, no. 6, pp. 353–365, Mar. 2018.

[3] S. Jonna and D. S. Subramaniam, “Molecular diagnostics and targeted therapies in non-small cell lung cancer (NSCLC): an update.,” Discov. Med., vol. 27, no. 148, pp. 167–170, Mar. 2019.

[4] I. Cricelli, E. Marconi, and F. Lapi, “Clinical Decision Support System (CDSS) in primary care: from pragmatic use to the best approach to assess their benefit/risk profile in clinical practice,” Curr. Med. Res. Opin., vol. 38, no. 5, pp. 827–829, May 2022.

[5] N. Veggiotti, L. Sacchi, and M. Peleg, “Enhancing the IDEAS Framework with Ontology: Designing Digital Interventions for Improving Cancer Patients’ Wellbeing.,” AMIA ... Annu. Symp. proceedings. AMIA Symp., vol. 2021, pp. 1186–1195, 2021.

[6] L. M. Hadjiiski et al., “Intraobserver Variability in Bladder Cancer Treatment Response Assessment With and Without Computerized Decision Support.,” Tomogr. (Ann Arbor, Mich.), vol. 6, no. 2, pp. 194–202, Jun. 2020.

[7] J. B. Li and Z. F. Jiang, “[Establishment and its application of Chinese society of clinical oncology artificial intelligence system (CSCO AI)].,” Zhonghua Yi Xue Za Zhi, vol. 100, no. 6, pp. 411–415, Feb. 2020.

[8] E. H. Shortliffe and M. J. Seplveda, “Clinical Decision Support in the Era of Artificial Intelligence.,” JAMA, vol. 320, no. 21, pp. 2199–2200, Dec. 2018.

[9] A. Kawamoto, K. Takenaka, R. Okamoto, M. Watanabe, and K. Ohtsuka, “Systematic review of artificial intelligence-based image

diagnosis for inflammatory bowel disease.," Dig. Endosc., vol. 34, no. 7, pp. 1311–1319, Nov. 2022.
[10] R. Cao, L. Gong, and D. Dong, "Pathological diagnosis and prognosis of Gastric cancer through a multi-instance learning method.," EBioMedicine, vol. 73, p. 103671, Nov. 2021.
[11] T. Beyer et al., "What scans we will read: imaging instrumentation trends in clinical oncology.," Cancer Imaging, vol. 20, no. 1, p. 38, Jun. 2020.
[12] T. J. Bright et al., "Effect of clinical decision-support systems: a systematic review.," Ann. Intern. Med., vol. 157, no. 1, pp. 29–43, Jul. 2012.
[13] B. Lo, "Sharing Clinical Trial Data," JAMA, vol. 313, no. 8, p. 793, Feb. 2015.
[14] D. B. Taichman et al., "Sharing Clinical Trial Data--A Proposal from the International Committee of Medical Journal Editors.," N. Engl. J. Med., vol. 374, no. 4, pp. 384–6, Jan. 2016.
[15] L. Muller et al., "An open access medical knowledge base for community driven diagnostic decision support system development," BMC Med. Inform. Decis. Mak., vol. 19, no. 1, p. 93, Dec. 2019.
[16] P. L. Elkin et al., "The introduction of a diagnostic decision support system (DXplainTM) into the workflow of a teaching hospital service can decrease the cost of service for diagnostically challenging Diagnostic Related Groups (DRGs).," Int. J. Med. Inform., vol. 79, no. 11, pp. 772–7, Nov. 2010.
[17] S. V. Pande et al., "Lightweight Artificial Intelligence for Secure Data Communication in Energy-Constrained Healthcare Devices," Comput. Intell. Neurosci., vol. 2022, pp. 1–9, Aug. 2022.
[18] P. Madhuri, N. Krishnaiah, P. Anandan, U. N. Nisha, A. K. Tamrakar, and P. Dileep, "Machine Learning Approach to Patient Health and Stress Monitoring System," in 2022 IEEE 2nd Mysore Sub Section International Conference (MysuruCon), IEEE, Oct. 2022, pp. 1–4.
[19] P. Anandan, S. Kokila, S. Elango, P. Gopinath, and P. Sudarsan, "Artificial Intelligence based Chat Bot for Patient Health Care," in 2022 International Conference on Computer Communication and Informatics (ICCCI), IEEE, Jan. 2022, pp. 1–4.
[20] A. P, S. K. A. M, C. C. Vignesh, and K. S, "Machine Learning Solution for Police Functions," in 2023 International Conference on Intelligent Data Communication Technologies and Internet of Things (IDCIoT), IEEE, Jan. 2023, pp. 463–469.